IAP20 Rec'd PCT/PTO 26 MAY 2006 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/012837

International Filing Date : 12 November 2004 (12.11.2004)

Priority Date(s) Claimed : 29 November 2003 (29.11.2003)

Applicant(s) (DO/EO/US) : Susanne MATHEUS, et al.

Title: SOLID FORMS OF ANTI-EGFR ANTIBODIES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

☒ .	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this infor disclosure statement is filed:						
		within three months of the filing date of a national application other than a CPA under § 1.53(d);					
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR					
		before the mailing of a first substantive office action (including after filing of an RCE).					
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ied in 37 C.F.R. § 1.97(b), but before the mailing date of:					
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and					

		is acco	empanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	is filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents Ui	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	<u>Materia</u>	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		-	s of materials listed but not attached were cited in an international search dated March 3, 2005.
		Not re	quired by 37 CFR § 1.98.
		Copie	s of the materials listed are attached (except for the foregoing).

Non-E	English l	Language References				
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).				
	\boxtimes	A foreign-language search report from a foreign patent office is provided, are pertinent parts are translated substantively below:				
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 				
		 A = document defining the general state of the art O = non-written disclosure P = intercalated document 				
		T = document cited to understand the theory or principle underlying the invention				
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date				
		D = cited in the application				
		L = cited for another reason				
		& = publication of member of same patent family				
	\boxtimes	Translation of other relevant information on foreign search report				
		In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.				
Other	Informa	ation .				
Payme	ent of F	ees Due (If Any):				
		ck for \$ covering the fee identified above is attached.				
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.				

IAP20 Rec'd PCT/PTO 26 MAY 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony v. Zelano, Reg. No. 27,969

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3169

Date: May 26, 2006

AJZ:aap:ssr

DOCKET NO.: MERCK-3169

IAP20 Rec'd PCT/PTO 26 MAY 2006

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete Port 58056 Substitute for form 1449A/PTO Application Number USNP 07 PCT/EP2004/012837 INFORMATION DISCLOSURE 12 November 2004 (12.11.2004) STATEMENT BY APPLICANT Susanne MATHEUS, et al. First Named Inventor Group Art Unit unknown (use as many sheets as necessary) **Examiner Name** unknown **MERCK-3169** Sheet of 2 Attorney Docket Number

U.S. PATENT DOCUMENTS								
Examiner Initials *	Cite No.1	U.S. Patent Docum	nent Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	001	6,217,866	B1	SCHLESSINGER, ET AL.	04-17-2001			
	002	2004/006212	A1	GOLDSTEIN, ET AL.	01-08-2004			
	003	5,558,864	Α	BENDIG, ET AL.	09-24-1996			
	004	2004/170632	A1	MAHLER, ET AL.	09-02-2004			
<u> </u>								

	FOREIGN PATENT DOCUMENTS									
			Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Office ³	Number⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶		
	005	EP	0 359 282	A2	RORER INTL INC.	03-21-1990		001		
	006	wo	03/053465	A2	MERCK PATENT GMBH, ET AL.	07-03-2003				
	007	wo	96/40210		IMCLONE SYSTEMS INC., ET AL.	12-19-1996		002		
	800	EP	0 531 472	В	MERCK PATENT GMBH, ET AL.	03-17-1993		003		
	009	wo	03/007988	A1	MERCK PATENT GMBH, ET AL.	01-30-2003		004		

C.	Data	
Examiner Signature	Date Considered	
Olgitatare	 	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

AP20 Rec'd PCT/PTO 26 MAY 2606

Please type a plus sign (+) inside this box -> 4	ptus sign (+) inside this box -> +
--	------------------------------------

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031**
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTO	1		Complete filt Known QNEAZ		
				Application Number	USNF-01-PCT/EP2004/012837	
INFO	RMATION	DIS	CLOSURE	Filing Date	12 November 2004 (12.11.2004)	
STA1	TEMENT BY	Y AF	PPLICANT	First Named Inventor	Susanne MATHEUS, et al.	
				Group Art Unit	unknown	
	(use as many she	ets as	necessary)	Examiner Name	unknown	
Sheet	2	of	2	Attorney Docket Number	MERCK-3169	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	010	BASELGA J: "THE EGFR AS A TARGET FOR ANTICANCER THERAPY-FOCUS ON CETUXIMAB" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, Bd. 37, SEPTEMBER 2001, PAGES 16-22, XP004307911; ISSN: 0959-8049					
	011	ABOU-JAWDE RONY ET AL: "AN OVERVIEW OF TARGETED TREATMENTS IN CANCER" CLINICAL THERAPEUTICS, Bd. 25, Nr. 8, AUGUST 2003, PAGES 2121-2137, XP002316108; ISSN: 0149-2918					
	012	HURRELL J.G.R.: "MONOCLONAL HYBRIDOMA ANTIBODIES: TECHNIQUES AND APPLICATIONS" 1982, CRC PRESS, BOCA RATON, FLORIDA, XP009043454; PAGE 51					
	013	DEUTSCHER M.P.: "GUIDE TO PROTEIN PURIFICATION" 1990, ACADEMIC PRESS, SAN DIEGO, XP002316109, PAGES 285-306					
		· ·					
		·					

Examiner	Date	
Signature	Considered	
Signature	Oorisidered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.